PD-1/PD-L1 pathway: current researches in cancer.

Cancer immunotherapy has been accompanied by promising results over the past few years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating apoptosis of antigen-specific T cells and inhibiting apoptosis of regulatory T cells. Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. Based on these perspectives, PD-1/PD-L1 axis is responsible for cancer immune escape and makes a huge effect on cancer therapy. This review is aimed to summarize the role of PD-1 and PD-L1 in cancer, looking forward to improve the therapy of cancer.

[1]  J. Lewin,et al.  Pembrolizumab‐induced mucositis in a patient with recurrent hypopharynx squamous cell cancer , 2020, The Laryngoscope.

[2]  G. Calin,et al.  MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. , 2019, Molecular aspects of medicine.

[3]  Arash Salmaninejad,et al.  PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy , 2019, Journal of cellular physiology.

[4]  S. Lantuejoul,et al.  Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. , 2019, Journal of thoracic disease.

[5]  Guang-Yu Lian,et al.  LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. , 2019, Life sciences.

[6]  Lin Xu,et al.  Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM‐JAK‐PD‐L1 pathway , 2019, Journal of cellular biochemistry.

[7]  Elham Sameiyan,et al.  The effect of medicinal plants on multiple drug resistance through autophagy: A review of in vitro studies , 2019, European journal of pharmacology.

[8]  Yonghao Yang,et al.  Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report. , 2019, Immunotherapy.

[9]  R. Chen,et al.  JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression. , 2019 .

[10]  A. Leha,et al.  Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. , 2019, Immunotherapy.

[11]  Ping Yang,et al.  PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. , 2019, Cancer letters.

[12]  Xiaomo Wu,et al.  Application of PD-1 Blockade in Cancer Immunotherapy , 2019, Computational and structural biotechnology journal.

[13]  E. D. de Vries,et al.  MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells , 2019, The Journal of pathology.

[14]  H. Qiu,et al.  FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway , 2019, The Journal of Immunology.

[15]  I. Berindan‐Neagoe,et al.  The Function of Non-Coding RNAs in Lung Cancer Tumorigenesis , 2019, Cancers.

[16]  G. Gupta,et al.  MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma. , 2019, Future medicinal chemistry.

[17]  Xiang Yu,et al.  Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer , 2019, Artificial cells, nanomedicine, and biotechnology.

[18]  Weili Zhao,et al.  MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells , 2019, Molecular Cancer.

[19]  Jun Yu,et al.  Autophagy inhibition enhances PD-L1 expression in gastric cancer , 2019, Journal of Experimental & Clinical Cancer Research.

[20]  D. Spector,et al.  MALAT1 long non-coding RNA and breast cancer , 2019, RNA biology.

[21]  D. Ogata,et al.  Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma , 2019, Current Treatment Options in Oncology.

[22]  A. Evens,et al.  The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma , 2019, Oncotarget.

[23]  W. Han,et al.  Effects of different levels of soluble PD-L1 protein on the growth of Lewis lung cancer transplanted tumor. , 2019, Journal of biological regulators and homeostatic agents.

[24]  A. Giobbie-Hurder,et al.  Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. , 2019, The Lancet. Oncology.

[25]  Jingxia Li,et al.  A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer , 2019, Cancers.

[26]  Kun-Kun Wang,et al.  MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection , 2018, Annals of Surgical Oncology.

[27]  Yaoyao Zhou,et al.  The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis , 2019, Front. Pharmacol..

[28]  Tao Xi,et al.  MiR-873/PD-L1 axis regulates the stemness of breast cancer cells , 2019, EBioMedicine.

[29]  Pramod Darvin,et al.  PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications , 2019, Journal of oncology.

[30]  S. Ansell,et al.  Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma , 2019, Blood Cancer Journal.

[31]  J. Hao,et al.  Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics , 2019, Current Oncology Reports.

[32]  Zhigui Li,et al.  PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway , 2019, Cell proliferation.

[33]  M. Iorio,et al.  WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer , 2019, Oncogene.

[34]  R. Pulido,et al.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma , 2019, Current Urology Reports.

[35]  E. Fuchs,et al.  WNT Signaling in Cancer Immunosurveillance. , 2019, Trends in cell biology.

[36]  Nina G. Steele,et al.  Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer , 2018, Oncotarget.

[37]  Gui-yuan Li,et al.  YAP1-induced MALAT1 promotes epithelial–mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer , 2018, Oncogene.

[38]  R. Huddart,et al.  From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. , 2018, European urology oncology.

[39]  Xu Li,et al.  Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout. , 2018, Human gene therapy.

[40]  J. Wolchok,et al.  Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab , 2018, Clinical Cancer Research.

[41]  R. Jonsson,et al.  Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy , 2018, Scandinavian journal of immunology.

[42]  M. Boerries,et al.  miR-146a Controls Immune Response in the Melanoma Microenvironment. , 2018, Cancer research.

[43]  M. Atkins,et al.  Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. , 2018, Cancer treatment reviews.

[44]  Y. Shi,et al.  ERα is a negative regulator of PD-L1 gene transcription in breast cancer. , 2018, Biochemical and biophysical research communications.

[45]  J. Tagne,et al.  NKX2-1-AS1 negatively regulates CD274/PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration , 2018, Scientific Reports.

[46]  P. Dong,et al.  Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion , 2018, Front. Oncol..

[47]  J. Wolchok,et al.  Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab , 2018, Clinical Cancer Research.

[48]  J. Taube,et al.  PD-L1 expression in medulloblastoma: an evaluation by subgroup , 2018, Oncotarget.

[49]  S. He,et al.  miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer , 2018, Clinical and Translational Oncology.

[50]  Katrien Van Roosbroeck,et al.  miR-155 in cancer drug resistance and as target for miRNA-based therapeutics , 2018, Cancer and Metastasis Reviews.

[51]  Arash Salmaninejad,et al.  PD-1 and cancer: molecular mechanisms and polymorphisms , 2018, Immunogenetics.

[52]  O. Liu,et al.  Mitogen-activated protein kinase signaling pathway in oral cancer. , 2017, Oncology letters.

[53]  G. Fontanini,et al.  Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma , 2017, Cancer Cell International.

[54]  A. Balar,et al.  Atezolizumab in invasive and metastatic urothelial carcinoma , 2017, Expert review of clinical pharmacology.

[55]  T. Catela Ivković,et al.  microRNAs as cancer therapeutics: A step closer to clinical application. , 2017, Cancer letters.

[56]  Shengwei Liu,et al.  PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways , 2017, Oncotarget.

[57]  Y. Maehara,et al.  A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. , 2017, Clinical lung cancer.

[58]  H. Yao,et al.  Rise of PD‐L1 expression during metastasis of colorectal cancer: Implications for immunotherapy , 2017, Journal of digestive diseases.

[59]  B. Fox,et al.  Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40 , 2017, Clinical Cancer Research.

[60]  B. Groner,et al.  Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.

[61]  Huirong Shi,et al.  Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. , 2017, Oncotarget.

[62]  T. Brummer,et al.  MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation , 2017, Leukemia.

[63]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[64]  Daniela Massi,et al.  PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. , 2017, Seminars in cancer biology.

[65]  Tasuku Honjo,et al.  Cancer immunotherapies targeting the PD-1 signaling pathway , 2017, Journal of Biomedical Science.

[66]  Z. Zeng,et al.  Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma , 2017, Oncotarget.

[67]  A. McMahon,et al.  Hedgehog Signaling: From Basic Biology to Cancer Therapy. , 2017, Cell chemical biology.

[68]  D. Schwartz,et al.  JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[69]  D. Schwartz,et al.  Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[70]  Y. Naito,et al.  The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. , 2017, Oncology reports.

[71]  T. Powles,et al.  A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. , 2017, Cancer treatment reviews.

[72]  Navneet Batra,et al.  PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation. , 2017, Current pharmaceutical design.

[73]  V. Boussiotis.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. , 2016, The New England journal of medicine.

[74]  Wen-Qi Jiang,et al.  PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma , 2016, Journal of Hematology & Oncology.

[75]  C. Cogoni,et al.  MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions , 2016, International journal of molecular sciences.

[76]  L. Gandhi,et al.  Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.

[77]  F. Bazer,et al.  Curcumin Suppresses Proliferation and Migration and Induces Apoptosis on Human Placental Choriocarcinoma Cells via ERK1/2 and SAPK/JNK MAPK Signaling Pathways1 , 2016, Biology of reproduction.

[78]  Li Liu,et al.  Up-regulation of LncRNA SNHG20 Predicts Poor Prognosis in Hepatocellular Carcinoma , 2016, Journal of Cancer.

[79]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  Qiuyang Zhang,et al.  PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. , 2016, American journal of clinical and experimental urology.

[81]  S. Murphy,et al.  Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. , 2015, Cancer research.

[82]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[83]  G. Kristiansen,et al.  The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer , 2015, Clinical Cancer Research.

[84]  Chuanhe Yang,et al.  The Role of miR‐21 in Cancer , 2015, Drug development research.

[85]  R. Mashima.  Physiological roles of miR‐155 , 2015, Immunology.

[86]  Z. Zeng,et al.  Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma , 2015, Oncotarget.

[87]  C. Rudd,et al.  ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy , 2015, EMBO molecular medicine.

[88]  P. Hersey,et al.  Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB , 2015, PloS one.

[89]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[90]  G. Freeman,et al.  Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression , 2015, Oncoimmunology.

[91]  Ren-Jie Wang,et al.  MicroRNA-873 (MiRNA-873) Inhibits Glioblastoma Tumorigenesis and Metastasis by Suppressing the Expression of IGF2BP1 , 2015, The Journal of Biological Chemistry.

[92]  Yan Liu,et al.  PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation , 2015, Journal of Translational Medicine.

[93]  S. Kaech,et al.  The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. , 2014, Immunity.

[94]  Lieping Chen,et al.  Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation , 2014, Cancer journal.

[95]  Haifeng Liu,et al.  Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1 , 2012, Proceedings of the National Academy of Sciences.

[96]  R. Ahmed,et al.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. , 2011, Immunity.

[97]  D. Iliopoulos,et al.  The negative costimulatory molecule PD‐1 modulates the balance between immunity and tolerance via miR‐21 , 2011, European journal of immunology.

[98]  G. Pinkus,et al.  Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells , 2011, Clinical Cancer Research.

[99]  M. Azuma,et al.  Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. , 2009, International journal of oncology.

[100]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[101]  H. Friess,et al.  Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. , 2008, Cancer letters.

[102]  Koichiro Matsumoto,et al.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers , 2007, Cancer Immunology, Immunotherapy.

[103]  G. Freeman,et al.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.

[104]  B. Neel,et al.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.

[105]  E. Birney,et al.  Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs , 2002, Nature.

[106]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[107]  M. Sakamoto,et al.  Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival , 2019, Modern Pathology.

[108]  C. Rudd,et al.  Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy. , 2018, Cancer research.

[109]  Jackeline Agorreta,et al.  A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. , 2017, Cancer discovery.

[110]  Charles S Bond,et al.  The ins and outs of lncRNA structure: How, why and what comes next? , 2016, Biochimica et biophysica acta.

[111]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[112]  Xijian Zhou,et al.  Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. , 2015, Molecular medicine reports.

[113]  Mary Collins,et al.  The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. , 2002, Annual review of immunology.